[Anti-epileptic properties of Ro5-4023, administered orally. Report on 40 cases].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D001552:Benzazepines / Q000008:administration & dosage* / Q000627:therapeutic use*; D002648:Child; D004357:Drug Synergism; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use; D007659:Ketones / Q000008:administration & dosage / Q000627:therapeutic use; D009574:Nitro Compounds / Q000008:administration & dosage / Q000627:therapeutic use
D000927:Anticonvulsants; D001463:Barbiturates; D001552:Benzazepines; D006827:Hydantoins; D007659:Ketones; D009574:Nitro Compounds
Propriétés antiépileptiques du Ro5-4023 per os. Considérations à propos de 40 cas.